2024 Q4 Form 10-Q Financial Statement
#000114036124046891 Filed on November 14, 2024
Income Statement
| Concept | 2024 Q4 | 2024 Q3 |
|---|---|---|
| Revenue | $0.00 | |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $3.375M | |
| YoY Change | -17.08% | |
| % of Gross Profit | ||
| Research & Development | $6.804M | |
| YoY Change | 5.51% | |
| % of Gross Profit | ||
| Depreciation & Amortization | $15.13K | |
| YoY Change | 51.3% | |
| % of Gross Profit | ||
| Operating Expenses | $10.18M | |
| YoY Change | -3.24% | |
| Operating Profit | -$10.18M | |
| YoY Change | -3.24% | |
| Interest Expense | -$548.0K | |
| YoY Change | -151.26% | |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$10.73M | |
| YoY Change | -1.13% | |
| Income Tax | $0.00 | |
| % Of Pretax Income | ||
| Net Earnings | -$10.73M | |
| YoY Change | -1.13% | |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | -$0.29 | |
| Diluted Earnings Per Share | -$0.29 | |
| COMMON SHARES | ||
| Basic Shares Outstanding | 37.41M | 36.82M |
| Diluted Shares Outstanding | 36.81M |
Balance Sheet
| Concept | 2024 Q4 | 2024 Q3 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $49.75M | |
| YoY Change | -8.38% | |
| Cash & Equivalents | $49.80M | |
| Short-Term Investments | ||
| Other Short-Term Assets | $2.380M | |
| YoY Change | -8.46% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $52.13M | |
| YoY Change | -8.28% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $147.5K | |
| YoY Change | 6.2% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | ||
| YoY Change | ||
| Total Long-Term Assets | $319.3K | |
| YoY Change | -8.61% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $52.13M | |
| Total Long-Term Assets | $319.3K | |
| Total Assets | $52.45M | |
| YoY Change | -8.28% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.301M | |
| YoY Change | -75.76% | |
| Accrued Expenses | $4.480M | |
| YoY Change | 20.01% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | |
| YoY Change | ||
| Long-Term Debt Due | $12.56M | |
| YoY Change | 12459.74% | |
| Total Short-Term Liabilities | $18.34M | |
| YoY Change | 100.36% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $12.11M | |
| YoY Change | -48.69% | |
| Other Long-Term Liabilities | ||
| YoY Change | ||
| Total Long-Term Liabilities | $12.11M | |
| YoY Change | -48.69% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $18.34M | |
| Total Long-Term Liabilities | $12.11M | |
| Total Liabilities | $30.45M | |
| YoY Change | -6.89% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$174.2M | |
| YoY Change | 30.36% | |
| Common Stock | $12.15K | |
| YoY Change | 18.73% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $22.00M | |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $52.45M | |
| YoY Change | -8.28% |
Cashflow Statement
| Concept | 2024 Q4 | 2024 Q3 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$10.73M | |
| YoY Change | -1.13% | |
| Depreciation, Depletion And Amortization | $15.13K | |
| YoY Change | 51.3% | |
| Cash From Operating Activities | -$8.000M | |
| YoY Change | 11.42% | |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $0.00 | |
| YoY Change | ||
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | ||
| YoY Change | ||
| Cash From Investing Activities | $0.00 | |
| YoY Change | ||
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 17.22K | |
| YoY Change | -97.85% | |
| NET CHANGE | ||
| Cash From Operating Activities | -8.000M | |
| Cash From Investing Activities | 0.000 | |
| Cash From Financing Activities | 17.22K | |
| Net Change In Cash | -7.982M | |
| YoY Change | 25.12% | |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$8.000M | |
| Capital Expenditures | $0.00 | |
| Free Cash Flow | -$8.000M | |
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
666770 | |
| CY2023Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
739404 | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2010874 | ||
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2219399 | ||
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2494558 | |
| CY2024Q3 | us-gaap |
Assets Current
AssetsCurrent
|
52131311 | |
| CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
59055075 | |
| CY2024Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
147479 | |
| CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
134132 | |
| CY2024Q3 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
171863 | |
| CY2023Q4 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
200873 | |
| CY2024Q3 | us-gaap |
Assets
Assets
|
52450653 | |
| CY2023Q4 | us-gaap |
Assets
Assets
|
59390080 | |
| CY2024Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1300920 | |
| CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6982824 | |
| CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4479541 | |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2424692 | |
| CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
13629977 | |
| CY2024Q3 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
12031986 | |
| CY2023Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
19506183 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
77659 | |
| CY2023Q4 | us-gaap |
Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
|
122973 | |
| CY2024Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
12150 | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
28960625 | ||
| us-gaap |
Operating Expenses
OperatingExpenses
|
32638273 | ||
| CY2024Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10178694 | |
| CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10519686 | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28960625 | ||
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32638273 | ||
| CY2023Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10849169 | |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10849169 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-29658032 | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-32043982 | ||
| CY2024Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.29 | |
| CY2024Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.29 | |
| CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.35 | |
| CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.35 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.82 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.82 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.04 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.04 | ||
| CY2024Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
36806592 | |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2080319 | |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9659918 | |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
41010953 | |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2105538 | |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
8849 | |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11534895 | |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
32444188 | |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
26130947 | |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1630011 | |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10603477 | |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
37183045 | |
| CY2024Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1795722 | |
| CY2024Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8327897 | |
| CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49751252 | |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
56560517 | |
| CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
170620641 | |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></span> <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(B)</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Use of estimates:</div> </td> </tr> </table> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> <span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses at the date of the condensed consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements. Actual results could differ from those estimates. The most significant estimate relates to the fair value of securities underlying stock-based compensation.</div> | ||
| CY2024Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
18340203 | |
| CY2024Q3 | us-gaap |
Liabilities
Liabilities
|
30449848 | |
| CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
33259133 | |
| CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
10921 | |
| CY2024Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
196147302 | |
| CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-174158647 | |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-144500615 | |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
26130947 | |
| CY2024Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
52450653 | |
| CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
59390080 | |
| CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6448528 | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18035762 | ||
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
20297066 | ||
| CY2024Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3374794 | |
| CY2023Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4071158 | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10924863 | ||
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12341207 | ||
| CY2024Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
10178694 | |
| CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
10519686 | |
| CY2024Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10726658 | |
| CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10726658 | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-29658032 | ||
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-32043982 | ||
| CY2024Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
36806592 | |
| CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
30910520 | |
| CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
30910520 | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
36107900 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
36107900 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
30715458 | ||
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
44002030 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
19494473 | |
| CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
30917870 | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
<div><span style="font-family: 'Times New Roman';"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;">Note 1 <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">– </span>Nature of Operations</span><span style="font-family: 'Times New Roman';"><br/> </span> </div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal;"><span style="font-size: 10pt; font-style: normal; font-weight: bold;"> <br/> </span></div> <div><span style="font-family: 'Times New Roman';"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS Biotech”), is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted immunotherapies designed to overcome limitations of current immunotherapy and vaccine technologies. The Company develops proprietary platforms designed to train and enable the immune system to attack and destroy disease; Versamune® and Versamune® in combination with PDS01ADC for treatments in oncology and Infectimune® for treatments in infectious diseases. When paired with an antigen, which is a disease-related protein that is recognizable by the immune system, Versamune® and Infectimune® have both been shown to induce, <span style="font-style: italic;">in vivo</span>, large quantities of high-quality, highly potent polyfunctional CD4 helper and CD8 killer T cells, a specific sub-type of T cell that is more effective at killing infected or target cells. PDS01ADC is a novel investigational tumor-targeting fusion protein of Interleukin 12 that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment and is designed to overcome the limitations of cytokine therapy which previously has resulted in high toxicity and limited therapeutic potential. The Company’s infectious disease candidate, Infectimune®, is of potential interest for use in universal influenza vaccines and is designed to promote the induction of disease-specific neutralizing antibodies. The Company’s immuno-oncology product candidates are of potential interest for use as a component of combination product candidates (for example in combination with other leading technologies such as immune checkpoint inhibitors) to provide more effective treatments across a range of advanced and/or refractory cancers. The Company is also evaluating its immunotherapies as monotherapies in early-stage disease. The Company is developing targeted product candidates to treat several cancer tumors, including Human Papillomavirus (HPV) associated cancer in head and neck squamous cell carcinoma, melanoma, colorectal, lung, breast and prostate<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.<br/> </span></span></div> | ||
| CY2024Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6803900 | |
| CY2024Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-547964 | |
| dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
PDS Biotechnology Corp | ||
| dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
| dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
26-4231384 | ||
| dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
303A College Road East | ||
| dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NJ | ||
| dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
08540 | ||
| dei |
City Area Code
CityAreaCode
|
800 | ||
| dei |
Local Phone Number
LocalPhoneNumber
|
208-3343 | ||
| dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.00033 per share | ||
| dei |
Trading Symbol
TradingSymbol
|
PDSB | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
| dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
| dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
| CY2024Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
37409137 | |
| CY2024Q3 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
12500000 | |
| CY2023Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
4166667 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
59742 | |
| CY2023Q4 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
55794 | |
| CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22000805 | |
| CY2024Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00033 | |
| CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00033 | |
| CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
75000000 | |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
33094521 | |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
33094521 | |
| CY2024Q3 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
1214734 | |
| CY2023Q3 | us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
1068887 | |
| us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
3577450 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-30527201 | ||
| us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-33450003 | ||
| CY2024Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2023Q3 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-869169 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1406021 | ||
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
30715458 | ||
| CY2023Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4588522 | |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
610000 | |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
243743 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
531091 | |
| CY2024Q2 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
267000 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-32043982 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5204005 | ||
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6259464 | ||
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
610000 | ||
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
0 | ||
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
160685 | ||
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
29010 | ||
| us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
30297 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-114499 | ||
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-73205 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-5681904 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
4147277 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2054849 | ||
| us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-4580981 | ||
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
0 | ||
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-239469 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-26795784 | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-25178960 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29000 | ||
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-29000 | ||
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
629591 | ||
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
8849 | ||
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
41366 | ||
| us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
46129 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
19427294 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5647467 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
20015519 | ||
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5610187 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-6809265 | ||
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-19568773 | ||
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
56560517 | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
73820160 | |
| CY2024Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
49751252 | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
2721354 | ||
| us-gaap |
Interest Paid Net
InterestPaidNet
|
2624653 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001472091 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-09-30 | ||
| dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
| dei |
Entity File Number
EntityFileNumber
|
001-37568 | ||
| dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Princeton | ||
| dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
| dei |
Entity Shell Company
EntityShellCompany
|
false | ||
| CY2024Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2380059 | |
| CY2024Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
36819810 | |
| CY2024Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
36819810 | |
| us-gaap |
Interest Expense Nonoperating
InterestExpenseNonoperating
|
3031129 | ||
| CY2023Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-329483 | |
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1566576 | ||
| us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-811730 | ||
| CY2024Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10726658 | |
| CY2023Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-10849169 | |
| CY2023Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2073607 | |
| CY2023Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
815202 | |
| CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10849169 | |
| CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24483828 | |
| CY2024Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1778272 | |
| CY2024Q3 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
67179 | |
| CY2024Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
98500 | |
| CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10726658 | |
| CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22000805 | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-29658032 | ||
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
267000 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
859135 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
391920 | ||
| us-gaap |
Depreciation
Depreciation
|
15654 | ||
| us-gaap |
Depreciation
Depreciation
|
12624 | ||
| CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
54251387 | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5984768 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5890131 | ||
| CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
49800000 | |
| CY2022Q3 | pdsb |
Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
|
150000000 | |
| CY2022Q3 | pdsb |
Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
|
50000000 | |
| CY2022Q3 | pdsb |
Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
|
50000000 | |
| CY2022Q3 | pdsb |
Commission Percentage
CommissionPercentage
|
0.03 | |
| CY2023 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
2642269 | |
| CY2023 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
16100000 | |
| us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
3428681 | ||
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
19400000 | ||
| CY2024Q3 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
0 | |
| CY2023Q2 | pdsb |
Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
|
1400000 | |
| CY2024Q2 | pdsb |
Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
|
900000 | |
| CY2024Q3 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
49751252 | |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
56560517 | |
| CY2024Q3 | us-gaap |
Area Of Real Estate Property
AreaOfRealEstateProperty
|
11200 | |
| CY2024Q3 | us-gaap |
Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
|
P40M | |
| CY2020Q2 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
700000 | |
| CY2020Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
700000 | |
| CY2020Q2 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.0915 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
0 | ||
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
239469 | ||
| pdsb |
Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
|
52388 | ||
| pdsb |
Finance Lease Principal And Interest Payments
FinanceLeasePrincipalAndInterestPayments
|
60684 | ||
| CY2024Q3 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
17462 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
|
69850 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
40108 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
26723 | |
| CY2024Q3 | pdsb |
Finance Lease Liability To Be Paid Year Four And Thereafter
FinanceLeaseLiabilityToBePaidYearFourAndThereafter
|
1 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
154144 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
16743 | |
| CY2024Q3 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
137401 | |
| pdsb |
Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
|
4 | ||
| pdsb |
Finance Lease Cost
FinanceLeaseCost
|
251959 | ||
| CY2024Q3 | us-gaap |
Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
|
0.0915 | |
| pdsb |
Lessee Finance Lease Monthly Rental Expense
LesseeFinanceLeaseMonthlyRentalExpense
|
6000 | ||
| CY2023 | us-gaap |
Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
|
151490 | |
| CY2024Q3 | pdsb |
Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
|
1735134 | |
| CY2023Q4 | pdsb |
Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
|
0 | |
| CY2024Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1070833 | |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
827863 | |
| CY2024Q3 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
1380498 | |
| CY2023Q4 | us-gaap |
Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
|
1289690 | |
| CY2024Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
292708 | |
| CY2023Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
306771 | |
| CY2024Q3 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
368 | |
| CY2023Q4 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
368 | |
| CY2024Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4479541 | |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
2424692 | |
| CY2024Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.5026 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.3707 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.4247 | ||
| CY2024Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0392 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0404 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0404 | ||
| CY2023Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y7M2D | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y21D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y21D | ||
| CY2024Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| CY2024Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0 | |
| CY2023Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.77 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.71 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.35 | ||
| us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | ||
| us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0 | ||
| CY2024Q3 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | ||
| CY2024Q3 | pdsb |
Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
|
0 | |
| CY2024Q3 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2024Q3 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2023Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-900000 | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1400000 | ||
| CY2024Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
68770 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
200770 | ||
| CY2023Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
106171 | |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
359373 | ||
| CY2022Q3 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
381625 | |
| CY2022Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
3.6685 | |
| CY2024Q3 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P10Y | |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
449329 | ||
| CY2024Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
1405513 | |
| CY2024Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1211375 | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
3566428 | ||
| CY2023Q3 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
1064300 | |
| us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
3016572 | ||
| CY2024Q3 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
305125 | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
859135 | ||
| CY2023Q3 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
158397 | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
391920 | ||
| CY2024Q3 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
38304 | |
| us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
151787 | ||
| CY2023Q3 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
32861 | |
| us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
164631 | ||
| CY2024Q3 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q3 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q3 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q3 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |
